Experimental combo aims to boost leukemia remission
NCT ID NCT05558124
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing the safety of combining two drugs—Vyxeos and gemtuzumab ozogamicin—for adults newly diagnosed with acute myeloid leukemia. Researchers want to find the best dose that doesn't cause severe side effects. The study will also look at how many patients achieve complete remission. Only 18 people aged 18 to 70 are being enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vyxeos (a chemotherapy drug combo) and gemtuzumab ozogamicin (a targeted antibody-drug)
What this could lead to
If it works, this could point toward a more effective treatment for newly diagnosed acute myeloid leukemia.
What could go wrong
This is a very early, small Phase 1 trial with only 18 participants. The main goal is safety, not proof of effectiveness. Side effects from the chemotherapy combination could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact